Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 29, 2002
Business Overview: Illumina is a developer of next-generation tools for the large-scale analysis of genetic variation and function, utilizing proprietary BeadArray and Oligator technologies. The company focuses on SNP genotyping, gene expression profiling, and proteomics to support personalized medicine and drug discovery.
Key Financial Metrics
| Metric (in thousands) | 2002 | 2001 |
|---|---|---|
| Total Revenue | $10,040 | $2,486 |
| Net Loss | $(40,331) | $(24,823) |
| Loss Per Share (Basic/Diluted) | $(1.31) | $(0.83) |
| Cash, Cash Equivalents & Investments | $66,294 | $93,786 |
| Working Capital | $58,522 | $91,452 |
| Total Debt (Long-term + Current) | $25,707 | $0 |
| Accumulated Deficit | $(90,424) | $(50,093) |
Revenue Breakdown (2002): Product revenue ($4.1M), Service revenue ($3.3M), and Research revenue ($2.6M).
Gross Margin: 52% on product and service revenues in 2002, up from 44% in 2001.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 304% to $10.0 million, driven by a 357% increase in product revenue (primarily oligonucleotide sales) and a 3,227% increase in service revenue (SNP genotyping contracts).
- Increased Losses: Net loss widened to $40.3 million from $24.8 million. This was primarily due to a $7.7 million litigation judgment charge, increased R&D expenses ($26.8M vs $20.7M), and higher SG&A expenses ($9.1M vs $5.7M).
- Debt Assumption: The company assumed a $26 million mortgage in January 2002 for the purchase of its San Diego facility, resulting in $2.3 million of interest expense in 2002 compared to $0.7 million in 2001.
- Liquidity: Cash and investments decreased by approximately $27.5 million, largely due to operating cash outflows of $26.4 million and capital expenditures of $11.8 million for the new facility.
Guidance, Outlook, Risks, and Contingencies
Outlook: Management expects to continue incurring substantial operating losses and negative cash flow for the foreseeable future as it scales manufacturing and expands sales infrastructure. Current cash resources are expected to fund operations for 18 to 24 months.
Material Risks & Contingencies:
- Applied Biosystems Litigation: A significant legal dispute exists with Applied Biosystems regarding a joint development agreement. Applied Biosystems has filed a patent infringement suit and sought arbitration, claiming Illumina's genotyping system is a collaboration product. Illumina has countersued for breach of contract. The outcome could materially affect operations.
- Employment Litigation: A $7.7 million judgment was recorded in 2002 regarding a wrongful termination lawsuit. Illumina is appealing; $12.5 million of marketable securities are currently restricted as collateral for the appeal bond.
- Commercialization Risk: The company has limited experience manufacturing commercial products at scale and relies on emerging markets for genetic analysis that may not develop as anticipated.
- Capital Needs: Additional funding may be required within the next 18-24 months to sustain growth and resolve legal contingencies.
Investor Verification Checklist
- Legal Exposure: Verify the status of the Applied Biosystems patent infringement suit and the wrongful termination appeal, as these represent significant contingent liabilities.
- Cash Runway: Confirm the sufficiency of the $66.3 million cash balance against projected burn rates, considering the restricted $12.5 million in investments.
- Revenue Quality: Assess the sustainability of revenue growth, noting that 26% of 2002 revenue came from government grants and research funding, which management expects to decline as a percentage of total revenue.
- Debt Service: Review the terms of the $26 million mortgage, including the $21.2 million balloon payment due in 2012.
- Stock-Based Compensation: Note that the company uses the intrinsic value method for stock options; pro forma net loss would be higher if the fair value method were adopted.